Figure 1 Viability of PC12 cells treated with Aβ25-35, (n = 6 for each group). The cells were treated with Aβ25-35 at the dosage of 25 μM, 35 μM, 45 μM, 55 μM, 65 μM for 48 h, after that, MTT assay used for measuring cell viability. *Comparing with control group, P < 0.05.
Figure 2 Viability of PC12 cells pretreated with VE and DHA, (n = 6 for each group). The cells were pretreated with VE (3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM) and DHA (3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM) for 4h, after that, 50 μM Aβ25-35 was added into the culture medium for another 24 h (A) or 48 h (B) incubation. MTT assay was used for measuring cell viability. *Comparing with control group, P < 0.05; #: comparing with Aβ25-35 treatment group, P < 0.05.
Figure 3 Viability of PC12 cells pretreated with VE+DHA, (n = 6 for each group).

The cells were pretreated with VE+DHA (6.25 μM VE +12.5μM DHA, 6.25 μM VE + 25 μM DHA, 3.125 μM VE +12.5μM DHA, 3.125 μM VE +25 μM DHA) for 4h, after that, 50 μM Aβ25-35 was added into the culture medium for another 24 h (A) or 48 h (B) incubation. MTT assay was used for measuring cell viability. *Comparing with control group, P < 0.05; #: comparing with Aβ25-35 treatment group, P < 0.05; a: comparing with Aβ25-35+VE6.25+DHA 25μM group, P < 0.05.